Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

13.60
+0.81506.38%
Post-market: 13.52-0.0750-0.55%19:51 EDT
Volume:4.12M
Turnover:54.96M
Market Cap:1.41B
PE:-2.61
High:13.71
Open:12.82
Low:12.73
Close:12.78
Loading ...

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Wave Life Sciences (WVE)

TIPRANKS
·
26 Mar

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

MT Newswires Live
·
26 Mar

BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)

Reuters
·
26 Mar

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

GlobeNewswire
·
26 Mar

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

Zacks
·
19 Mar

BUZZ-H.C. Wainwright starts coverage on Intellia with 'buy' rating on optimism for heart disease therapies

Reuters
·
06 Mar

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

MT Newswires Live
·
05 Mar

Intellia Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
05 Mar

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Mar

Intellia Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
05 Mar

Stock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target

Stock Track
·
04 Mar

Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus

TIPRANKS
·
04 Mar

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

MT Newswires Live
·
04 Mar

Intellia Therapeutics price target lowered to $50 from $90 at Truist

TIPRANKS
·
04 Mar

Bank of America Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
02 Mar

Intellia Therapeutics’ Promising Future: Buy Rating Backed by Strong Financials and Program Advancements

TIPRANKS
·
02 Mar

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks
·
01 Mar